Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today that the FDA has approved the Company’s treatment protocol for prGCD, the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE